Unfortunately, the positive outcomes of the preclinical observations have not been observed in randomized clinical trials in patients with acute coronary syndrome (ACS), in which reassembled HDL containing ApoAI Milano or wild-type ApoAI were infused weekly [49,50]. The gene discussed is APOA1; the disease is acute coronary syndrome.